-
1
-
-
33646119401
-
Hematopoietic stem-cell transplantation
-
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.
-
(2006)
N Engl J Med
, vol.354
, pp. 1813-1826
-
-
Copelan, E.A.1
-
2
-
-
8944220233
-
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
-
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
-
(1996)
N Engl J Med
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
-
3
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
-
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
-
(1995)
N Engl J Med
, vol.333
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
-
4
-
-
24644503670
-
Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials
-
Stem Cell Trialists' Collaborative Group
-
Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5074-5087
-
-
-
5
-
-
0344925935
-
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)
-
Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95:3702-9.
-
(2000)
Blood
, vol.95
, pp. 3702-3709
-
-
Champlin, R.E.1
Schmitz, N.2
Horowitz, M.M.3
-
6
-
-
9044236159
-
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
-
Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-7.
-
(1996)
Lancet
, vol.347
, pp. 353-357
-
-
Schmitz, N.1
Linch, D.C.2
Dreger, P.3
-
7
-
-
0027945942
-
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells
-
Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994;12:2176-86.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2176-2186
-
-
Nademanee, A.1
Sniecinski, I.2
Schmidt, G.M.3
-
8
-
-
85047698716
-
Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy
-
Weaver CH, Buckner CD, Curtis LH, et al. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. Bone Marrow Transplant 2002;29:159-64.
-
(2002)
Bone Marrow Transplant
, vol.29
, pp. 159-164
-
-
Weaver, C.H.1
Buckner, C.D.2
Curtis, L.H.3
-
9
-
-
0034097402
-
Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
-
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-77.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1360-1377
-
-
Siena, S.1
Schiavo, R.2
Pedrazzoli, P.3
Carlo-Stella, C.4
-
10
-
-
0034614576
-
Stem cells: Units of development, units of regeneration, and units in evolution
-
Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000;100:157-68.
-
(2000)
Cell
, vol.100
, pp. 157-168
-
-
Weissman, I.L.1
-
11
-
-
0036800296
-
The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice
-
Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002;16:1992-2003.
-
(2002)
Leukemia
, vol.16
, pp. 1992-2003
-
-
Lapidot, T.1
Kollet, O.2
-
12
-
-
0036754547
-
Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells
-
Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973-81.
-
(2002)
Exp Hematol
, vol.30
, pp. 973-981
-
-
Lapidot, T.1
Petit, I.2
-
13
-
-
0026779726
-
Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma
-
Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992;90:358-67.
-
(1992)
J Clin Invest
, vol.90
, pp. 358-367
-
-
Teixido, J.1
Hemler, M.E.2
Greenberger, J.S.3
Anklesaria, P.4
-
14
-
-
2642710893
-
The chemokine receptor CXCR- 4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1
-
Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR- 4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998;91:4523-30.
-
(1998)
Blood
, vol.91
, pp. 4523-4530
-
-
Mohle, R.1
Bautz, F.2
Rafii, S.3
Moore, M.A.4
Brugger, W.5
Kanz, L.6
-
15
-
-
0031026475
-
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood
-
Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-20.
-
(1997)
J Exp Med
, vol.185
, pp. 111-120
-
-
Aiuti, A.1
Webb, I.J.2
Bleul, C.3
Springer, T.4
Gutierrez-Ramos, J.C.5
-
16
-
-
0037237648
-
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide
-
Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111:187-96.
-
(2003)
J Clin Invest
, vol.111
, pp. 187-196
-
-
Levesque, J.P.1
Hendy, J.2
Takamatsu, Y.3
Simmons, P.J.4
Bendall, L.J.5
-
17
-
-
0036265635
-
Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment
-
Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002;30:440-9.
-
(2002)
Exp Hematol
, vol.30
, pp. 440-449
-
-
Levesque, J.P.1
Hendy, J.2
Takamatsu, Y.3
Williams, B.4
Winkler, I.G.5
Simmons, P.J.6
-
18
-
-
0035469853
-
Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor
-
Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001;98:1289-97.
-
(2001)
Blood
, vol.98
, pp. 1289-1297
-
-
Levesque, J.P.1
Takamatsu, Y.2
Nilsson, S.K.3
Haylock, D.N.4
Simmons, P.J.5
-
19
-
-
0032960960
-
Management strategies for the hard-to-mobilize patient
-
Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999;23 suppl 2:S29-33.
-
(1999)
Bone Marrow Transplant
, vol.23
, Issue.SUPPL. 2
-
-
Stiff, P.J.1
-
20
-
-
0028282857
-
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
-
Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-94.
-
(1994)
Blood
, vol.83
, pp. 3787-3794
-
-
Haas, R.1
Mohle, R.2
Fruhauf, S.3
-
21
-
-
0037355362
-
The whys and hows of hematopoietic progenitor and stem cell mobilization
-
Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003;31:319-29.
-
(2003)
Bone Marrow Transplant
, vol.31
, pp. 319-329
-
-
Kessinger, A.1
Sharp, J.G.2
-
22
-
-
0031937912
-
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma
-
Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998;4:311-6.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 311-316
-
-
Moskowitz, C.H.1
Glassman, J.R.2
Wuest, D.3
-
23
-
-
7844239444
-
Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies
-
Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998;103:235-42.
-
(1998)
Br J Haematol
, vol.103
, pp. 235-242
-
-
Ketterer, N.1
Salles, G.2
Moullet, I.3
-
24
-
-
0027888222
-
Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents
-
Neben S, Hellman S, Montgomery M, Ferrara J, Mauch P. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993;21:156-62.
-
(1993)
Exp Hematol
, vol.21
, pp. 156-162
-
-
Neben, S.1
Hellman, S.2
Montgomery, M.3
Ferrara, J.4
Mauch, P.5
-
25
-
-
0028885705
-
Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts
-
Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-8.
-
(1995)
Blood
, vol.86
, pp. 3970-3978
-
-
Dreger, P.1
Kloss, M.2
Petersen, B.3
-
26
-
-
34548138921
-
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
-
Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035- 42.
-
(2007)
Leukemia
, vol.21
, pp. 2035-2042
-
-
Kumar, S.1
Dispenzieri, A.2
Lacy, M.Q.3
-
27
-
-
45149129384
-
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (letter)
-
author reply 1-2
-
Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (letter). Leukemia 2008;22:1280-1; author reply 1-2.
-
(2008)
Leukemia
, vol.22
, pp. 1280-1281
-
-
Mazumder, A.1
Kaufman, J.2
Niesvizky, R.3
Lonial, S.4
Vesole, D.5
Jagannath, S.6
-
28
-
-
0028133466
-
Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
-
Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-31.
-
(1994)
Br J Haematol
, vol.87
, pp. 825-831
-
-
Bensinger, W.I.1
Longin, K.2
Appelbaum, F.3
-
29
-
-
0037326714
-
Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: Influence of age, prior therapy, platelet count and mobilization regimen
-
Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120:413-23.
-
(2003)
Br J Haematol
, vol.120
, pp. 413-423
-
-
Morris, C.L.1
Siegel, E.2
Barlogie, B.3
-
30
-
-
67349243088
-
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
-
Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:718-23.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 718-723
-
-
Popat, U.1
Saliba, R.2
Thandi, R.3
-
31
-
-
44649143334
-
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
-
Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008;22:1282-4.
-
(2008)
Leukemia
, vol.22
, pp. 1282-1284
-
-
Paripati, H.1
Stewart, A.K.2
Cabou, S.3
-
32
-
-
0029092359
-
Factors that influence collection and engraftment of autologous peripheral-blood stem cells
-
Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-55.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2547-2555
-
-
Bensinger, W.1
Appelbaum, F.2
Rowley, S.3
-
33
-
-
0031024323
-
Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma
-
Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997;15:535- 46.
-
(1997)
J Clin Oncol
, vol.15
, pp. 535-546
-
-
Watts, M.J.1
Sullivan, A.M.2
Jamieson, E.3
-
34
-
-
0029916837
-
The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis
-
Schots R, Van Riet I, Damiaens S, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant 1996;17:509-15.
-
(1996)
Bone Marrow Transplant
, vol.17
, pp. 509-515
-
-
Schots, R.1
Van Riet, I.2
Damiaens, S.3
-
35
-
-
0029939222
-
Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer
-
Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996;14:1114-21.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1114-1121
-
-
Schwella, N.1
Beyer, J.2
Schwaner, I.3
-
36
-
-
0037406452
-
An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors
-
Ford CD, Chan KJ, Reilly WF, Petersen FB. An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003;43:622-5.
-
(2003)
Transfusion
, vol.43
, pp. 622-625
-
-
Ford, C.D.1
Chan, K.J.2
Reilly, W.F.3
Petersen, F.B.4
-
37
-
-
0345700849
-
Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim
-
Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003;43:495-501.
-
(2003)
Transfusion
, vol.43
, pp. 495-501
-
-
Moncada, V.1
Bolan, C.2
Yau, Y.Y.3
Leitman, S.F.4
-
38
-
-
3042753920
-
-
Hematology American Society of Hematology Education Program, Washington, DC
-
Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology American Society of Hematology Education Program, Washington, DC, 2003:419-37.
-
(2003)
Stem cell mobilization
, pp. 419-437
-
-
Cottler-Fox, M.H.1
Lapidot, T.2
Petit, I.3
-
39
-
-
0029952312
-
Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation
-
Anderlini P, Przepiorka D, Huh Y, et al. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol 1996;93:940-2.
-
(1996)
Br J Haematol
, vol.93
, pp. 940-942
-
-
Anderlini, P.1
Przepiorka, D.2
Huh, Y.3
-
40
-
-
74549204059
-
-
Product information. Leukine (sargrastim). Seattle, WA: Bayer Healthcare Pharmaceuticals, April 2008.
-
Product information. Leukine (sargrastim). Seattle, WA: Bayer Healthcare Pharmaceuticals, April 2008.
-
-
-
-
41
-
-
74549122128
-
-
Product information. Neupagen (filgrastim). Thousand Oaks, CA: Amgen Inc., 1991-1996.
-
Product information. Neupagen (filgrastim). Thousand Oaks, CA: Amgen Inc., 1991-1996.
-
-
-
-
42
-
-
33646490285
-
Lineage-specific hematopoietic growth factors
-
Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006;354:2034-45.
-
(2006)
N Engl J Med
, vol.354
, pp. 2034-2045
-
-
Kaushansky, K.1
-
43
-
-
9044248242
-
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells
-
Winter JN, Lazarus HM, Rademaker A, et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996;14:277-86.
-
(1996)
J Clin Oncol
, vol.14
, pp. 277-286
-
-
Winter, J.N.1
Lazarus, H.M.2
Rademaker, A.3
-
44
-
-
0035496919
-
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
-
Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059-64.
-
(2001)
Blood
, vol.98
, pp. 2059-2064
-
-
Narayanasami, U.1
Kanteti, R.2
Morelli, J.3
-
45
-
-
0030813148
-
Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
-
Spitzer G, Adkins D, Mathews M, et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997;20:921-30.
-
(1997)
Bone Marrow Transplant
, vol.20
, pp. 921-930
-
-
Spitzer, G.1
Adkins, D.2
Mathews, M.3
-
46
-
-
8544226948
-
Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: High-dose cyclophosphamide plus GM-CSF vs G-CSF alone
-
Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997;20:211-7.
-
(1997)
Bone Marrow Transplant
, vol.20
, pp. 211-217
-
-
Alegre, A.1
Tomas, J.F.2
Martinez-Chamorro, C.3
-
47
-
-
0034485697
-
Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?
-
Dazzi C, Cariello A, Rosti G, et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma? Leuk Lymphoma 2000;39:301-10.
-
(2000)
Leuk Lymphoma
, vol.39
, pp. 301-310
-
-
Dazzi, C.1
Cariello, A.2
Rosti, G.3
-
48
-
-
0024434868
-
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for auto-transplantation
-
Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for auto-transplantation. Lancet 1989;2:580-5.
-
(1989)
Lancet
, vol.2
, pp. 580-585
-
-
Gianni, A.M.1
Siena, S.2
Bregni, M.3
-
49
-
-
0032902383
-
Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization
-
Gazitt Y, Freytes CO, Callander N, et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999;8:173-83.
-
(1999)
J Hematother
, vol.8
, pp. 173-183
-
-
Gazitt, Y.1
Freytes, C.O.2
Callander, N.3
-
50
-
-
0036182360
-
Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): A randomized evaluation of different doses of rhG-CSF
-
Demirer T, Ayli M, Ozcan M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002;116:468-74.
-
(2002)
Br J Haematol
, vol.116
, pp. 468-474
-
-
Demirer, T.1
Ayli, M.2
Ozcan, M.3
-
51
-
-
0033987790
-
Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells
-
Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000;18:43-53.
-
(2000)
J Clin Oncol
, vol.18
, pp. 43-53
-
-
Weaver, C.H.1
Schulman, K.A.2
Wilson-Relyea, B.3
Birch, R.4
West, W.5
Buckner, C.D.6
-
52
-
-
0029047168
-
Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma
-
Schiller G, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995;86:390-7.
-
(1995)
Blood
, vol.86
, pp. 390-397
-
-
Schiller, G.1
Vescio, R.2
Freytes, C.3
-
53
-
-
0032761285
-
Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
-
Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-85.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3776-3785
-
-
Moskowitz, C.H.1
Bertino, J.R.2
Glassman, J.R.3
-
54
-
-
85047699168
-
Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma
-
Pavone V, Gaudio F, Guarini A, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;29:285-90.
-
(2002)
Bone Marrow Transplant
, vol.29
, pp. 285-290
-
-
Pavone, V.1
Gaudio, F.2
Guarini, A.3
-
55
-
-
33645325987
-
ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: A single institution result of 127 patients
-
Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006;37:277-82.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 277-282
-
-
Akhtar, S.1
Tbakhi, A.2
Humaidan, H.3
El Weshi, A.4
Rahal, M.5
Maghfoor, I.6
-
56
-
-
20144362352
-
ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: Comparison with high-dose cyclophosphamide plus G-CSF
-
Lee JL, Kim S, Kim SW, et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005;35:449-54.
-
(2005)
Bone Marrow Transplant
, vol.35
, pp. 449-454
-
-
Lee, J.L.1
Kim, S.2
Kim, S.W.3
-
57
-
-
0033829481
-
-
Holowiecki J, Wojciechowska M, Giebel S, et al. Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients. Transplant Proc 2000;32:1412-5.
-
Holowiecki J, Wojciechowska M, Giebel S, et al. Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients. Transplant Proc 2000;32:1412-5.
-
-
-
-
58
-
-
0033516303
-
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization
-
Reiser M, Josting A, Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999;23:1223-8.
-
(1999)
Bone Marrow Transplant
, vol.23
, pp. 1223-1228
-
-
Reiser, M.1
Josting, A.2
Draube, A.3
-
59
-
-
0033762415
-
Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non-Hodgkin's lymphoma
-
Ashihara E, Shimazaki C, Okano A, Hatsuse M, Inaba T, Nakagawa M. Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non-Hodgkin's lymphoma. Haematologica 2000;85:1112-4.
-
(2000)
Haematologica
, vol.85
, pp. 1112-1114
-
-
Ashihara, E.1
Shimazaki, C.2
Okano, A.3
Hatsuse, M.4
Inaba, T.5
Nakagawa, M.6
-
60
-
-
0032915879
-
Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens
-
Stewart DA, Guo D, Morris D, et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999;23:111-7.
-
(1999)
Bone Marrow Transplant
, vol.23
, pp. 111-117
-
-
Stewart, D.A.1
Guo, D.2
Morris, D.3
-
61
-
-
0028856612
-
An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
-
Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
-
(1995)
Blood
, vol.86
, pp. 3961-3969
-
-
Weaver, C.H.1
Hazelton, B.2
Birch, R.3
-
62
-
-
0342680002
-
Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF
-
Gomez-Espuch J, Moraleda JM, Ortuno F, et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant 2000;25:231-5.
-
(2000)
Bone Marrow Transplant
, vol.25
, pp. 231-235
-
-
Gomez-Espuch, J.1
Moraleda, J.M.2
Ortuno, F.3
-
63
-
-
0029021397
-
DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma
-
Olivieri A, Offidani M, Ciniero L, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995; 16:85-93.
-
(1995)
Bone Marrow Transplant
, vol.16
, pp. 85-93
-
-
Olivieri, A.1
Offidani, M.2
Ciniero, L.3
-
64
-
-
0031897817
-
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma
-
Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998;16:1547-53.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1547-1553
-
-
Desikan, K.R.1
Barlogie, B.2
Jagannath, S.3
-
65
-
-
0033748383
-
Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: A randomized prospective study
-
Gazitt Y, Callander N, Freytes CO, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 2000;9:737-48.
-
(2000)
J Hematother Stem Cell Res
, vol.9
, pp. 737-748
-
-
Gazitt, Y.1
Callander, N.2
Freytes, C.O.3
-
66
-
-
12444306329
-
G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: Results depend on degree of previous pretreatment
-
Milone G, Leotta S, Indelicato F, et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant 2003;31:747-54.
-
(2003)
Bone Marrow Transplant
, vol.31
, pp. 747-754
-
-
Milone, G.1
Leotta, S.2
Indelicato, F.3
-
67
-
-
49449091143
-
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
-
Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 1045-1056
-
-
Pusic, I.1
Jiang, S.Y.2
Landua, S.3
-
68
-
-
0034120373
-
Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
-
Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44: 1667-73.
-
(2000)
Antimicrob Agents Chemother
, vol.44
, pp. 1667-1673
-
-
Hendrix, C.W.1
Flexner, C.2
MacFarland, R.T.3
-
69
-
-
64249173226
-
The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
-
De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-64.
-
(2009)
Biochem Pharmacol
, vol.77
, pp. 1655-1664
-
-
De Clercq, E.1
-
70
-
-
74549140386
-
-
Product information. Mozobil (plerixafor). Cambridge, MA: Genzyme Corporation, December 2008.
-
Product information. Mozobil (plerixafor). Cambridge, MA: Genzyme Corporation, December 2008.
-
-
-
-
71
-
-
58149182700
-
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma
-
Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009;15:39-46.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 39-46
-
-
Stewart, D.A.1
Smith, C.2
MacFarland, R.3
Calandra, G.4
-
72
-
-
23944525352
-
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
-
Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-74.
-
(2005)
Blood
, vol.106
, pp. 1867-1874
-
-
Flomenberg, N.1
Devine, S.M.2
Dipersio, J.F.3
-
73
-
-
40249093217
-
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data
-
Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8.
-
(2008)
Bone Marrow Transplant
, vol.41
, pp. 331-338
-
-
Calandra, G.1
McCarty, J.2
McGuirk, J.3
-
74
-
-
53749085874
-
A Phase II Study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma
-
Cashen A, Lopez S, Gao F, et al. A Phase II Study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253-61.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 1253-1261
-
-
Cashen, A.1
Lopez, S.2
Gao, F.3
-
75
-
-
70350450580
-
Phase III, prospective, randomized, double-blind, placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma
-
DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III, prospective, randomized, double-blind, placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4767-4773
-
-
DiPersio, J.F.1
Micallef, I.N.2
Stiff, P.J.3
-
76
-
-
67651089936
-
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
-
DiPersio J SE, Stadtmauer EA, Nademanee AP, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6.
-
(2009)
Blood
, vol.113
, pp. 5720-5726
-
-
DiPersio, J.S.1
Stadtmauer, E.A.2
Nademanee, A.P.3
-
77
-
-
58249125135
-
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient
-
Stiff P, Micallef I, MccCarthy P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009;15:249-56.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 249-256
-
-
Stiff, P.1
Micallef, I.2
MccCarthy, P.3
-
78
-
-
67649980456
-
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): An institutional experience
-
Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009;43:909-17.
-
(2009)
Bone Marrow Transplant
, vol.43
, pp. 909-917
-
-
Fowler, C.J.1
Dunn, A.2
Hayes-Lattin, B.3
-
79
-
-
70350566151
-
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: Results from the plerixafor NHL phase 3 study rescue protocol
-
Micallef IN, Stiff PJ, DiPersio JF. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009;15:1578-86.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 1578-1586
-
-
Micallef, I.N.1
Stiff, P.J.2
DiPersio, J.F.3
|